Varda Space Industries provides in-space manufacturing services by operating production facilities in low Earth orbit and returning finished products to Earth using reentry capsules. Clients send materials or designs to Varda’s in-orbit production line, where microgravity enables manufacturing processes not possible on Earth, before the goods are sent back via capsules. The company builds end-to-end in-orbit infrastructure, including production equipment and reliable reentry systems, to make low Earth orbit more accessible for multiple industries. Its goal is to industrialize low Earth orbit by enabling production in space and bringing products back to Earth for commercial use.
Company Size
201-500
Company Stage
Series D
Total Funding
$609.5M
Headquarters
El Segundo, California
Founded
2020
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Exciting team of professionals at the top of their field to working by your side
Working in El Segundo, CA - an awesome Southern California beach city with quick access to entertainment and outdoor activities
Equity in a fully funded space startup that is about to go through massive growth
Company parties and generally a fun atmosphere
401(k)
Unlimited PTO
Health insurance
Lunch and snacks provided on site. Dinners twice a week for those working late.
Parental leave
Varda raises $251M to leverage gravity in space for drug production. October 2, 2026 | Capitalizing on space's microgravity, the United Therapeutics-partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules. Varda Space Industries has raised $251 million to manufacture medicines in space for patients on Earth. Lux Capital and Natural Capital co-led the series D round for Varda, valuing the company at $1.6 billion, Reuters reported on Wednesday. Varda, which was set up in 2021 by former SpaceX engineer Will Bruey and Founders Fund partner Delian Asparouhov, has now raised $598 million in total since its founding. The California-based startup launched its first mission in 2023 and has completed six successful reentries. Varda has booked 28 launches with SpaceX and other providers between 2027 and 2029, Reuters reported on Wednesday. The support reflects the belief that Varda is "the first and only company delivering a real cadence of launches and reentries," Shahin Farshchi, partner at Lux Capital, said in a prepared statement. Space's lower levels of gravity, which make objects seem weightless, influence crystal formation in ways that could affect drug properties such as stability and bioavailability. Evidence of the microgravity's effect on drug molecules has fueled decades of research. NASA sponsored a report on the topic in 1978, and Merck's space station research informed its subcutaneous Keytruda formulation. With the cost of sending a kilogram to orbit falling 96% from 1960 to 2025 and forecast to drop further through 2040, one barrier to commercially viable drug production in space is lowering. Varda is among the companies seeking to capitalize on the shift. The company launches its capsules into orbit aboard commercial rockets, such as SpaceX's Falcon 9. The capsules contain equipment for processing pharmaceuticals in orbit. After completing processing, the capsule separates from the orbital satellite, returns to Earth and is recovered for analysis. Other groups have shown that a small quantity of space-grown crystals can support multiple terrestrial production batches. In May, United Therapeutics partnered with Varda to develop improved formulations of treatments for rare lung indications. The pact supports the exploration of "how space-based manufacturing could contribute to significant improvements for rare pulmonary disease treatments," United Therapeutics CEO Martine Rothblatt said in a statement at the time. Varda and United Therapeutics have competition in the race to discover and make drugs in orbit. Space Microgravity Development (SpaceMD), part of the space and defense technology company Redwire, has given former Merck researcher Paul Reichert a strategic advisory role as it pursues orbital research and manufacturing. SpaceMD has signed a contract for a mission using Starfall, SpaceX's recently launched in-space manufacturing program. And Voyager Technologies operates research facilities aboard the International Space Station. The company's capacity, which supports a microgravity-enabled drug discovery pact with Space LiinTech, will be enhanced next year with a system for automated drug screening. Nick is a freelance writer who has been reporting on the global life sciences industry since 2008.
Varda Space Industries has launched two spacecraft on a single rocket for the first time, marking a shift to fleet operations. The company's W-8 and W-9 vehicles lifted off aboard SpaceX's Transporter-18 rideshare mission from Vandenberg Space Force Base. Both spacecraft carry payloads from government and commercial partners. W-8 hosts Canopy Aerospace & Defense's heat shield monitoring system and thermal protection materials funded by the Air Force Research Laboratory. W-9 carries a hypersonic navigation system and advanced heatshield materials from Syensqo. Varda has safely reentered six capsules since 2024. The dual launch demonstrates the company's increasing mission cadence as it scales orbital pharmaceutical processing and hypersonic reentry operations. The vehicles will be managed from Varda's expanded Mission Operations facility in El Segundo.
Varda pockets $251m to back space-based pharma processing mission. Varda secures this capital as drugmakers tout the potential of manufacturing in microgravity conditions to create differentiated medicines. Varda Space Industries has banked $251m in a Series D financing to scale its in-space pharmaceutical processing operations, as the industry increasingly recognises the potential of producing drugs in microgravity conditions. With cash provided by Lux Capital and Natural Capital, as well as contributions from other players like Kholsa Ventures and the Founders Fund, Varda plans to enhance the frequency and speed at which it can launch and return materials between Earth and orbit, as well as deepen its partnerships with the pharma industry. The company secured this funding, which brings its total capital raised to $598m, as it looks to debut the first space-made medicine on the pharmaceutical market. Unlike Earth-based drug processing, manufacturing in space is performed in zero-gravity conditions. By producing medicines in space without the constraints of gravity, Varda proposes that active pharmaceutical ingredients (APIs) can be crystallised in ways that are impossible on Earth - potentially allowing for the market entry of a new swathe of medicines with differential patient benefits. Thus far, Varda has already had some success in the space, with the company completing its first mission launch in 2023. Since then, the microgravity-led processing company has completed six successful re-entry missions. With its eyes on further expansion, Varda is also planning more than 12 more launches and re-entries up to 2028, as it looks to become the leading space life sciences company. "We started Varda with the conviction that the first product manufactured in space and consumed on Earth would be a pharmaceutical," commented Delian Asparouhov, co-founder and president of Varda. "This round gives us the resources to increase our cadence, deepen our pharmaceutical partnerships, and get closer to delivering the first medicine made in space," he added. Global governments bet on in-orbit medicines manufacturing. Varda secures this capital as space-based drug production garners increasing interest from global governments. This includes the UK government, which is actively looking to create a favourable regulatory environment for space-manufactured drugs in Britain by debuting a regulatory sandbox focused on re-entry. This is designed to streamline the licensing process for scaled in-orbit operations and facilitate the sector's growth. On top of these regulatory shifts, the British government has also financially backed UK-based space biotech startup, BioOrbit, which is currently running feasibility studies focused on crystallising biologics in-orbit to allow for the creation of home-administered cancer therapies. The Swiss government is also looking to be part of the action, as it recently joined forces with the UK to figure out how best regulators, investors and the government can harmoniously address and overcome current challenges linked to space manufacturing. Give your business an edge with its leading industry insights.
Varda Space Industries raises $251M from ceo Will Bruey. El Segundo-based Varda Space Industries, microgravity-enabled, raised $251M Series A+ from CEO Will Bruey. El Segundo-based Varda Space Industries, microgravity-enabled, raised $251M Series A+ from... Traded Editorial Varda Space Industries raises $251M in a series a+ from CEO Will Bruey.
/PRNewswire/ -- Varda Space Industries announced a Series D fundraising round today, bringing the total amount of capital raised by the microgravity-enabled...